ALX Oncology Holdings Inc. (ALXO): Analyst Targets Suggest +318% Upside on Key Data Readouts

Key Takeaways

• The central target of $4.60 is the arithmetic mean of five verified analyst price targets, which range from $4.00 to $6.00.
• At a recent price near $1.10, reaching $4.60 would require an upside of roughly 318%, a very large move by any standard.
• Targets come from Wells Fargo ($5.00), UBS ($6.00), H.C. Wainwright ($4.00), Piper Sandler ($4.00), and Jefferies ($4.00); a separate firm, LifeSci Capital, holds a Hold rating with no target.
• The strongest support comes from a cash runway through the first half of 2028 and encouraging biomarker data suggesting CD47 expression predicts response to evorpacept.
• The biggest risk is that ALX Oncology has no approved products, and its valuation depends on a Phase 2 readout expected around mid-2027.
• You can find more information about this ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
• Explore Trending AI Robots to see how AI-driven strategies monitor stocks like this for changing conditions.

Breaking Down the Analyst Consensus

The $4.60 figure reflects five current price targets with identifiable firms and dates: Wells Fargo at $5.00 (October 2026), UBS at $6.00 (May 2026), and H.C. Wainwright, Piper Sandler, and Jefferies each at $4.00. Averaging these gives $4.60, with a range of $4.00 to $6.00. Even the lowest target sits well above the recent price, a reflection of how much value analysts believe successful data could unlock rather than a forecast of near-term performance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The views are uniformly bullish but diverge on magnitude. The higher targets from UBS and Wells Fargo embed greater confidence in evorpacept's biomarker-driven strategy, while the $4.00 targets reflect a more conservative stance on a stock still years from potential commercialization. LifeSci Capital's Hold rating adds a note of caution, though it carries no price target. None of these figures is a guarantee; they represent research expectations, not outcomes.

Current Market Position and Path Toward the Target

With shares near $1.10, the stock would need to more than quadruple to reach $4.60. That qualifies as a very large move. ALX Oncology is pre-revenue, so the path is binary: positive data would likely re-rate the shares dramatically, while disappointing results could compress the stock toward its cash value. The company reported $153.4 million in cash, equivalents, and investments as of June 30, 2026, enough to fund operations into the first half of 2028, which reduces immediate financing risk but does not by itself create value.

Factors That Could Support a Move Toward the Target

Evorpacept's development rests on a CD47 biomarker hypothesis that has gained independent validation. Data from the Phase 2 ASPEN-06 gastric cancer trial and a Phase 1b/2 breast cancer study with Jazz Pharmaceuticals' zanidatamab both suggested that patients with high CD47 expression show the most durable responses. Management is targeting the post-ENHERTU HER2-positive breast cancer setting, an area with meaningful unmet need. The company's second program, the EGFR-directed antibody-drug conjugate ALX2004, adds pipeline diversification, with Phase 1 safety data expected in the second half of 2026.

Risks That Could Keep the Target Out of Reach

The central risk is clinical. The pivotal catalyst is topline data from the Phase 2 ASPEN-09-Breast trial, expected around mid-2027; until then, the stock may trade on sentiment rather than fundamentals. CD47 has a long history of clinical setbacks across the industry, and even ALX Oncology's own management acknowledges historical skepticism about the target. As a pre-revenue biotech, the company also faces binary-outcome risk, potential future dilution despite the extended runway, and competition in a crowded HER2-positive breast cancer landscape.

Technical Levels and Market Structure

At a price near $1.10, the stock trades in a low-priced range where small absolute moves produce large percentage swings. Analyst targets between $4.00 and $6.00 sit far above any recent trading zone, meaning there is limited near-term technical reference to these levels. Investors should watch whether the stock can hold above the $1.00 psychological level, a breach of which could signal renewed selling pressure, while any catalyst-driven advance would need to clear prior multi-month highs before the analyst range becomes technically relevant.

Time Horizon and Key Items to Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though ALX Oncology's key catalyst — the ASPEN-09-Breast topline readout — is expected around mid-2027, potentially beyond that window. Near-term items to monitor include Phase 1 safety data for ALX2004 in the second half of 2026, quarterly cash-burn updates, and any analyst revisions or financing announcements. Investors should also track the company's upcoming earnings report, with the next estimate around early November 2026.

Using AI Daily Buy/Sell Signals in Practice

From what I see, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-dependent name like ALXO, these signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Traders seeking a more systematic edge can use the signals to complement their own research and react more quickly to changing conditions.

Final Assessment

The $4.60 central target, derived from five analyst price targets spanning $4.00 to $6.00, implies a roughly 318% move from a price near $1.10. The bullish case rests on validated CD47 biomarker data, a cash runway into 2028, and two clinical programs approaching meaningful readouts. The bearish case centers on the absence of revenue, CD47's checkered history, and a pivotal data readout still roughly a year away. With such a wide gap between price and target, the outcome will be determined less by valuation math than by the quality of the ASPEN-09-Breast results and continued pipeline execution. No outcome is assured.

Exploring Tickeron AI Tools for Biotech Analysis

In my view, one tool that stands out for this kind of research is Tickeron’s AI Trend Prediction Engine, which I sometimes reference when evaluating how clinical catalysts might influence price action over longer horizons. It helps put the binary nature of events like the mid-2027 readout into a broader market context without replacing fundamental work. I’m watching this closely as part of a balanced approach to high-risk names.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume